Skip To Main Content
Sarah Djabarouti on Muck Rack

Sarah Djabarouti

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sarah

Contact Sarah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Preliminary pharmacokinetic investigation of two discoidin domain receptor 2 inhibitors in murine plasma and brain using liquid chromatography–tandem mass spectrometry analysis

|
By Audrey Burban, Ahmad Sharanek, Stéphane Bouchet, Mathieu Molimard, Sarah Djabarouti, Joris Guyon, Paul Gueroue, Guillaume Bougueon, Dominique Ducint
| Nature Verified
Abstract Owing to its involvement in extracellular matrix–glial cell interactions, discoidin domain receptor 2 (DDR2) has emerged as a promising pharmacological target in various human diseases, including cancers and neurodegenerative disorders. Two allosteric inhibitors, WRG-28 and DDR2-IN-1, selectively target DDR2.
Open in Who Shared Issue with article?

Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?

|
By Cedric Carrie, Julien Ollivier, Nicolas d’Houdain, Sarah Djabarouti
| asm.org
Pharmacology Julien Ollivier, Cédric Carrié, Nicolas d’Houdain, Sarah Djabarouti, Laurent Petit, Fabien Xuereb, Rachel Legeron, Matthieu Biais, Dominique Breilh DOI: 10.1128/AAC.02134-18 ABSTRACT The objective of the present study was to determine whether augmented renal clearance (ARC) impacts negatively on ceftriaxone pharmacokinetic (PK)/pharmacodynamic (PD) target attainment in critically ill patients. Over a 9-month period, all critically ill patients treated with ceftriaxone were eligible.
Open in Who Shared Issue with article?
See all 2 articles